

# PRECEPTORSHIP PROGRAMME

## Metastatic Bladder and Kidney Cancer

Multidisciplinary management,  
standards of care, therapeutic targets  
and future perspectives

**LUGANO**  
SWITZERLAND

**29-30 NOVEMBER 2019**

**Co-Chairs**

Aristotelis Bamias, GR  
Camillo Porta, IT

# ESMO PRECEPTORSHIP PROGRAMME METASTATIC BLADDER AND KIDNEY CANCER

Multidisciplinary management, standards of care,  
therapeutic targets and future perspectives

**Lugano, Switzerland  
29-30 November 2019**

---

**CO-CHAIRS:** Aristotelis Bamias, Greece  
Camillo Porta, Italy

**SPEAKERS:** Maurizio Brausi, Italy  
Patrizia Giannatempo, Italy  
Viktor Grünwald, Germany  
Dimitrios Kardamakis, Greece  
Holger Moch, Switzerland  
Alessandro Volpe, Italy

---

## LEARNING OBJECTIVES

- To learn about fundamentals of molecular pathology and diagnosis as contributing factors to heterogeneity in bladder and kidney cancer
- To understand essentials in the assessment and multidisciplinary treatment of bladder and kidney cancer
- To learn about advances in treatment and novel targets in bladder and kidney cancer

---

## ACCREDITATION

The programme of this event has been accredited with **8 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to [esmo.org](http://esmo.org).

---

## ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



---

## ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Ginevra 4  
6900 Lugano  
Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



## Friday, 29 November 2019

<b>09:00-09:15</b> 15'	<b>Opening and welcome</b>	
15'	Welcome from ESMO - Objectives and scientific introduction	Aristotelis Bamias, GR Camillo Porta, IT
<b>09:15-10:10</b> 55'	<b>SESSION 1</b> <b>Personalized therapy in bladder cancer and Renal Cell Cancer (RCC)</b>	<b>Chair:</b> <b>Viktor Grünwald, DE</b>
20'	The search for biomarkers in bladder cancer	Patrizia Giannatempo, IT
20'	The search for biomarkers in RCC	Viktor Grünwald, DE
15'	Discussion	Faculty
<b>10:10-10:40</b>	<b>Coffee break</b>	
<b>10:40-12:10</b> 90'	<b>SESSION 2</b> <b>Multidisciplinary approach in metastatic urothelial cancer and RCC</b>	<b>Chair:</b> <b>Maurizio Brausi, IT</b>
15'	The role of surgery in metastatic bladder cancer	Maurizio Brausi, IT
20'	RCC: Surgery in metastatic disease	Alessandro Volpe, IT
10'	Discussion	Faculty
45'	Participants clinical case discussion (3x15')	Faculty
<b>12:10-13:10</b>	<b>Lunch</b>	
<b>13:10-15:00</b> 110'	<b>SESSION 3</b> <b>Metastatic disease: Systemic therapy</b>	<b>Chair:</b> <b>Camillo Porta, IT</b>
15'	Metastatic bladder cancer: Chemotherapy	Aristotelis Bamias, GR
20'	mRCC: Anti-angiogenic therapy	Camillo Porta, IT
20'	Metastatic bladder cancer: Immunotherapy	Aristotelis Bamias, GR
15'	mRCC: Immunotherapy	Viktor Grünwald, DE
10'	Discussion	Faculty
30'	Participants clinical case discussion (2x15')	Faculty
<b>15:00-15:30</b>	<b>Coffee break</b>	

<b>15:30-16:40</b> 70'	<b>SESSION 4</b> <b>Pathology and molecular pathology</b>	<b>Chair:</b> <b>Patrizia Giannatempo, IT</b>
20'	Bladder cancer	Holger Moch, CH
20'	Renal cancer	Holger Moch, CH
15'	Clinical application	Patrizia Giannatempo, IT
15'	Discussion	Faculty
<b>19:00</b>	<b>Dinner</b>	

## Saturday, 30 November 2019

<b>09:00-10:10</b> 70'	<b>SESSION 5</b> <b>Debates of the day</b>	<b>Chair:</b> <b>Aristotelis Bamias, GR</b>
20'	Systemic chemotherapy is the standard for metastatic urothelial cancer: - YES - NO	Aristotelis Bamias, GR Camillo Porta, IT
15'	Discussion	Faculty
20'	Which immunotherapy is the standard first-line therapy for mRCC: - Immune doublet - Immune combos with a TKI	Viktor Grünwald, DE Camillo Porta, IT
15'	Discussion	Faculty

<b>10:10-10:40</b>	<b>Coffee break</b>
--------------------	---------------------

<b>10:40-11:50</b> 70'	<b>SESSION 6</b> <b>Side effects</b>	<b>Chair:</b> <b>Viktor Grünwald, DE</b>
10'	Chemotherapy	Aristotelis Bamias, GR
15'	TKIs and mTOR Inhibitors	Camillo Porta, IT
15'	Immunotherapy	Camillo Porta, IT
30'	Participants clinical case discussion (2x15')	Faculty

<b>11:50-12:05</b> 15'	<b>Conclusion and farewell</b>	<b>Aristotelis Bamias, GR</b> <b>Camillo Porta, IT</b>
---------------------------	--------------------------------	---

<b>12:05-13:00</b>	<b>Lunch</b>
--------------------	--------------

**Note:** Each 15 minute slot for clinical case discussion includes 7' case presentation and 8' Q&A / panel discussion